Evidence map›Paper›PMID 38244173›Full record

ArticleJournal of neuro-oncology2024

Craniospinal irradiation for CNS leukemia: rates of response and durability of CNS control.

Maryam Ebadi, Margaret Morse, Ted Gooley, Ralph Ermoian, Lia M Halasz, Simon S Lo, Jonathan T Yang, Molly H Blau, Mary-Elizabeth Percival, Ryan D Cassaday and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Maryam EbadiDepartment of Radiation Oncology, University of Washington, 1959 NE Pacific Street, 98195, Seattle, WA, USA.
Margaret MorseUniversity of Washington School of Medicine, Seattle, WA, USA.
Ted GooleyClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Ralph ErmoianDepartment of Radiation Oncology, University of Washington, 1959 NE Pacific Street, 98195, Seattle, WA, USA.
Lia M HalaszDepartment of Radiation Oncology, University of Washington, 1959 NE Pacific Street, 98195, Seattle, WA, USA.
Simon S LoDepartment of Radiation Oncology, University of Washington, 1959 NE Pacific Street, 98195, Seattle, WA, USA.
Jonathan T YangDepartment of Radiation Oncology, University of Washington, 1959 NE Pacific Street, 98195, Seattle, WA, USA.
Molly H BlauDepartment of Radiation Oncology, University of Washington, 1959 NE Pacific Street, 98195, Seattle, WA, USA.
Mary-Elizabeth PercivalClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Ryan D CassadayClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Jerome GraberDepartment of Neurology, Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA, USA.
Lynne P TaylorDepartment of Neurology, Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA, USA.
Vyshak VenurClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Yolanda D TsengDepartment of Radiation Oncology, University of Washington, 1959 NE Pacific Street, 98195, Seattle, WA, USA. Ydt2@uw.edu.
University of Washington · USFred Hutch Cancer Center · USUniversity of Washington Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeManagement of CNS involvement in leukemia may include craniospinal irradiation (CSI), though data on CSI efficacy are limited.

methodsWe retrospectively reviewed leukemia patients who underwent CSI at our institution between 2009 and 2021 for CNS involvement. CNS local recurrence (CNS-LR), any recurrence, progression-free survival (PFS), CNS PFS, and overall survival (OS) were estimated.

resultsOf thirty-nine eligible patients treated with CSI, most were male (59%) and treated as young adults (median 31 years). The median dose was 18 Gy to the brain and 12 Gy to the spine. Twenty-five (64%) patients received CSI immediately prior to allogeneic hematopoietic cell transplant, of which 21 (84%) underwent total body irradiation conditioning (median 12 Gy). Among 15 patients with CSF-positive disease immediately prior to CSI, all 14 assessed patients had pathologic clearance of blasts (CNS-response rate 100%) at a median of 23 days from CSI start. With a median follow-up of 48 months among survivors, 2-year PFS and OS were 32% (95% CI 18-48%) and 43% (95% CI 27-58%), respectively. Only 5 CNS relapses were noted (2-year CNS-LR 14% (95% CI 5-28%)), which occurred either concurrently or after a systemic relapse. Only systemic relapse after CSI was associated with higher risk of CNS-LR on univariate analysis. No grade 3 or higher acute toxicity was seen during CSI.

conclusionCSI is a well-tolerated and effective treatment option for patients with CNS leukemia. Control of systemic disease after CSI may be important for CNS local control. CNS recurrence may reflect reseeding from the systemic space.

Indexed as

Brain NeoplasmsCentral Nervous System NeoplasmsCraniospinal IrradiationHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteCranial IrradiationFemaleHumansMaleRecurrenceRetrospective StudiesYoung AdultCNSCraniospinal irradiationLeukemiaProtonsToxicity

Identifiers

PMID38244173
OpenAlexW4391051595

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.